addition, most current therapeutic options have been ineffective.
PDTC and ATC have been identified in coexistence with well-differentiated areas, suggesting that these tumors can arise from pre-existing PTC and/or FTC cases (2) (3) (4) . This process of dedifferentiation is supported by the detection, in PDTC and ATC, of BRAF and RAS genes mutations (commonly found in WDTC) in association with later acquired alterations in TP53, CTNNB1 (␤-catenin) and PIK3CA genes (2) (3) (4) (5) (6) .
By global gene expression profiling, authors have described that compared with WDTC cases, PDTC and ATC exhibit deregulation of different cellular events, eg, focal adhesion, cell motility, TGF-␤ signaling, chromosome segregation, cell cycle and proliferation (7) (8) (9) . Previously, we have compared the transcriptional profiles of PDTC, WDTC and normal thyroid samples, and found that PDTC presented molecular signatures mainly related to cell proliferation, poor prognosis, spindle assembly checkpoint and cell adhesion (10) .
In the present study, to further elucidate the main molecular pathways and alterations contributing to PDTC and ATC, we profiled the ATC gene expression, and analyzed the mutational status of N-, H-, K-RAS, BRAF, TP53, CTNNB1 and PIK3CA genes in a series of 48 tumors (26 ATC and 22 PDTC), 4 ATC-and 2 PDTC-derived cell lines. Additionally, in accordance with the deregulated pathways in ATC and PDTC, we sequenced the coding regions and splice sites of five cyclin-dependent kinase inhibitors (CDKI) 
], and of the PTEN gene, which are critical regulators of the cell cycle/proliferation. We also analyzed AXIN1 gene, which encodes a negative regulator of WNT signaling pathway, and was found to be mutated in 81.8% of ATC from a Japanese series (11) .
Materials and Methods

Tissue samples
A total of 11 classical variant of PTC (cPTC), 12 follicular variant (fvPTC) of PTC, 11 FTC and 7 normal thyroid tissues samples (all taken from the opposite lobe of thyroid tumors) were used in the study. All these samples, 12 PDTC and 15 ATC were obtained at time of surgery, and were immediately frozen in liquid nitrogen. 8 PDTC and 5 ATC were preserved as formalinfixed paraffin embedded samples (FFPE). 2 PDTC and 7 ATC were collected during fine-needle aspiration biopsies (FNAB), being conserved in RLT buffer (RNeasy Mini Kit, Quiagen, Hamburg, GmbH, Germany) with 1% (v/v) 2-Mercaptoethanol and maintained at -70°C. Histological classifications followed previously described criteria (12) . A pool of human thyroid total RNA (BD Bioscience, Franklin Lakes, NJ, USA), 2 PDTC-derived (T243 and T351) and 4 ATC-derived (T235, T238, T241 and C643) cell lines were also used.
All samples were obtained with permission, and the project was approved by our institution ethical committee.
Array hybridization and data analysis
RNA integrity was assessed by micro capillary electrophoresis (Agilent 2100 Bioanalyzer, Santa Clara, CA, USA). Samples were processed following the Whole Transcript Sense Target Labeling Assay from Affymetrix (Santa Clara, CA, USA) and were hybridized in GeneChip Gene 1.0 ST Array (Affymetrix).
Microarray data analysis
Partek Genomics Suite Software (Partek Inc, St Louis, MO, USA) was used for unsupervised hierarchical clustering of the samples, applying Pearson's dissimilarity and Ward's clustering method. Robust multiarray average method (13) was first employed for array data normalization and expression levels determination.
DNA-Chip Analyzer (dChip) 2010.01 software (14) was used to obtain differentially expressed genes between ATC and normal thyroid samples. Arrays were normalized with the invariant set normalization method and gene-level expression was determined by summarizing the multiple probes across the gene (median of 26 probes per gene) into a single gene level-probe set expression, using model-based expression analysis with perfect match-only model. Gene level-probe sets that were absent in all samples or those that did not change across samples (coefficient of variation lower than 0.2 and higher than 10) were eliminated from further analysis. Gene level-probe sets were considered to be differentially expressed, with a lower 90% limit of the confidence interval (CI) of the fold change (ratio of the expression level in the two groups), equal or higher than two-fold, and with an unpaired t test considered significant at P Յ .001. OntoExpress (15) and Pathway-Express (16) from Onto-Tools package were used for functional profiling according to cellular components and for pathway impact analysis of differentially expressed genes, respectively.
Gene set enrichment analysis (GSEA) software (17) , using the GenePattern platform (18) , was applied to the complete list of 33252 probe-sets, to determine Gene Ontology-defined gene sets (groups of genes, which share common features) associated with increased or decreased expression in ATC. Statistical significance was estimated by a nominal P value obtained by gene set permutation (70 000 permutations performed). P values were corrected for multiple hypothesis testing, using false discovery rate (FDR) and family wise-error rate. Gene sets were considered significant at P Յ .05 and FDR Յ 0.25.
Venn diagram analysis was performed using GenePattern platform (18) .
The expression data set has been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and is accessible through GEO Series accession number GSE53072. 
Statistical analysis
GraphPad Prism version 4.00 (GraphPad Software, Inc.) was implemented for statistical analysis and for comparison of survival distributions by logrank test. Differences were considered significant at P Յ .05.
Results
ATC transcriptome analyses
We determined the ATC global gene expression profile, using RNA extracted from 3 fresh-frozen tumors and 2 FNAB, and compared it with 3 normal thyroid tissues and a commercial pool of normal human thyroid RNA. Unsupervised analysis using hierarchical clustering showed that all 5 ATC samples clustered together, separated from the normal samples ( Figure 1 ). Gene Sets Enrichment Analysis identified sets of genes with increased expression in ATC, markedly related to cell cycle and division processes, checkpoints and chromosome segregation (Supplemental Table 2 ). Underexpressed genes in ATC were mainly related to tight junctions, intercellular junctions and oxidoreductase activity (Supplemental Table 3 ).
Gene expression comparison analysis showed that ATC and normal thyroid samples had 1333 differentially expressed genes, defined as those with expression level (set at the lower limit of 90% confidence) equal, or higher, than two-fold between the defined two groups, with a statistical significance equal or lower than 0.001. Among these genes, 983 (74%) were downregulated and 350 (26%) were upregulated in ATC. Pathway impact analysis pointed out several deregulated pathways in ATC (Table  1) . Adherens junction (Supplemental Figure 1) , tight junction (Supplemental Figure 2) and focal adhesion (Supplemental Figure 3 ) pathways, comprised mainly downregulated genes, contrary to cell cycle, which was completely associated with overexpressed genes (Supplemental Figure  4) . TGF-␤ signaling pathway (Supplemental Figure 5) was associated with increased expression of genes involved in TGF-␤ ligand reception, but to decreased expression of components from bone morphogenetic protein (BMP) signaling. Functional profiling of the differentially expressed genes revealed the involvement of different cell components, such as cytoskeleton, spindle, microtubules, chromosomes and the aforementioned cell junctions (Supplemental Table 4 ).
Previously, we analyzed the gene expression of cPTC, fvPTC, FTC and PDTC (10) (microarrays data accessible through GEO Series accession number GSE53157). To compare the ATC gene expression with our previous work, we searched for differentially expressed genes relatively to normal thyroid that ATC had in common with each other tumor types ( Figure 2 ). Of the 1333 genes in ATC, 71 were common to cPTC, 31 to fvPTC, 30 to FTC and 34 to PDTC. Six genes were shared between all tumors (Supplemental File 1). Exclusion of all these common genes left 1216 genes that are specifically deregulated, only in ATC (Supplemental File 2).
Validation of gene expression results
Cyclin-dependent kinase inhibitor 3 (CDKN3) was the most overexpressed gene in ATC. We searched for the presence of CDKN3 abnormal splice variants, associated with this upregulation. The RT-PCR amplification of CDKN3 and the separation of each of the amplicons by subcloning, revealed two expression patterns: in 6 normal thyroid tissues, only CDKN3 full-length transcripts were present, whereas in 3 ATC samples, 2 PDTC cell lines and 4 ATC cell lines, we detected full-length transcripts in combination with splice variants (Figure 3a ). These splice variants were characterized by the skipping of the entire exon 2. Quantitative RT-PCR assays allowed the differential analysis of the expression levels due to splice variants or due to full-length transcript, in 46 thyroid tumors and 7 normal samples ( Figure 3b ). Despite a higher total CDKN3 (full length transcript plus splice variant) expression in some WDTC, and in PDTC (P Ͻ .05) relatively to normal samples, most the tumors expressed only the fulllength transcript. In ATC tumors and cell lines, we also found a statistically significant overexpression of total CDKN3 transcription, relatively to normal tissue (P Ͻ .01 and P Ͻ .001, respectively), but, in these groups, total CDKN3 quantification was significantly higher than the correspondent quantification of sole full-length transcript (P ϭ .0122 and P ϭ .0111, respectively). So, contrarily to WDTC and PDTC, CDKN3 upregulation in ATC and cell lines was associated with expression of abnormal splice variants. We used TaqMan RT-PCR to further validate our microarray results for SNAI2 gene, in a set of thyroid tumor samples and cell lines (Figure 4 ). In agreement with the global gene expression, SNAI2 was significantly more expressed in ATC than in normal tissues (P Ͻ .01). A subgroup of 8 ATC was clearly distinguished, with relative expression levels higher than 3-fold. The ATC cell line (C643) and a minimally invasive FTC also had more than 3-fold expression. SNAI2 expression was not correlated to age at diagnosis or tumor size in ATC (data not shown).
ATC and PDTC mutational analysis
A total of 22 PDTC, 26 ATC, 2 PDTC-and 4 ATC-cell lines were screened for sequence variations in 14 genes. Overall, 59 different alterations, totalizing 72 mutated sequences, were identified (Supplemental Table 5 ) and were present in 13 PDTC (59%) and 20 ATC (77%). Among cell lines, in three ATC cell lines were found 9 mutated sequences. Eight of the alterations were predicted in silico to be benign and were not taken into account. Three variants identified in the AXIN1 gene and detected in tumor samples, were also present in the corresponding normal tissues. RAS, TP53, PTEN, CDKN1B and PIK3CA genes were mutated at similar frequencies (14%-27%) in PDTC (Table 2 and Supplemental Table 6 ). By contrast, TP53 and RAS were the most frequently mutated genes (42% and 31%, respectively) in ATC (Table 2 and   Supplemental Table 7 ), and alterations in other genes (PIK3CA, BRAF, PTEN, CDKN2A, CDKN2C and AXIN1) were less frequent (4%-10%). None of the mutations had a significant association with ATC or PDTC ( Table 2 ). In 48 screened tumors, only one ATC, out of seventeen TP53 mutated samples and out of twelve RAS mutated samples, had both mutations in coexistence, suggesting that these events were mutually exclusive (P ϭ .0354, Fisher's exact test).
Correlation of molecular data with clinicalpathological features and patients survival
Comparisons between PDTC and ATC groups showed that ATC patients had higher age at presentation (P ϭ .0009) and considerably lower median survival (P ϭ .0001) (Supplemental Table 8 ). We attempted to correlate 
Discussion
Although representing a minority of thyroid malignancies, PDTC and particularly ATC, may contribute for more than half of the deaths attributable to thyroid cancer. ATC are associated with elderly patients, presenting as a rapidly growing mass with widespread invasion of soft tissues, and extensive hemorrhagic and necrotic areas (12) . Contrariwise, PDTC definition has not been clear, and a definite designation as a separate entity, intermediate between WDTC and ATC (12), was only obtained in 2004. Subsequent studies demonstrated that PDTC patients had distinctive older age, more aggressive features and poorer prognosis relatively to WDTC cases (19) . In agreement with others (20, 21) , in this study we found ATC patients had statistically significant older age and lower survival than PDTC patients.
Due to the high risks of recurrence and metastasis, unfeasible surgical resection and failure of conventional Expression levels of full-length transcription and total (full-length and splice variants) transcription were both determined for each sample, normalized with the hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) expression and determined relatively to a calibrator. Error bars denote standard error of the mean. The P values for difference in mean expression were performed using the Kruskal-Wallis with Dunn's multiple comparison test. *P values calculated by paired t test; fvPTC -follicular variant of papillary thyroid carcinoma; cPTC -classic papillary thyroid carcinoma; FTC -follicular thyroid carcinoma; PDTCpoorly differentiated thyroid carcinoma; ATC -anaplastic thyroid carcinoma.
chemotherapy and radiotherapy, novel treatment strategies against PDTC and ATC are particularly needed. Therefore, complete molecular profiling of these tumors is considerably important. Previously, we analyzed the genome-wide expression of PDTC. In the present study, we expanded our analysis to ATC and, in addition, searched for genetic alterations potentially driving the aberrant expression and aggressiveness of PDTC and ATC. Three previously published works have assessed the gene expression of primary ATC tumors. Salvatore and collaborators have analyzed the transcriptional profiles of 5 ATC, 10 PTC and 4 normal thyroid samples (7) . Among the 914 differentially expressed genes between ATC and normal thyroid tissues, found in Salvatore's work, 76 of these genes were also present in our data. In agreement with that study, most of the common genes were upregulated and associated with proliferation, cell cycle and chromosome segregation. Montero-Conde et al, have compared a group of 7 ATC and 6 PDTC with 31 WDTC (7 FTC and 24 PTC) (8) . A comparison of our results with the data from Montero-Conde and collaborators was not possible, as the complete list of differentially expressed genes was not available. Nevertheless, these authors have described deregulated molecular profiles (proliferation, chromosome segregation, TGF-␤ pathway and thyroid functions), which we have also identified in our cases.
Hébrant et al, studied 11 ATC, 48 PTC and 23 normal thyroid tissues (22) . 2164 genes distinguished ATC from normal thyroid tissues, and among these, 391 genes were common to our analysis. These genes were, in agreement with the other studies, indicative of enhanced proliferation, TGF-␤ pathway upregulation and repression of thyroid-related functions.
Analyzing ATC differentially expressed genes relatively to normal thyroid tissue, we found, in accordance with others (7, 23, 24) , that the majority were underexpressed, a pattern also present in PDTC and FTC (10, 23) . From the comparison of differentially expressed genes relatively to normal tissues, between ATC and our previous studied tumors (10), we observed 1216 genes that were only associated with ATC, and thus represent specific pathways involved in ATC progression.
As previously observed (8, (22) (23) (24) , loss of thyroid follicular cell identity in ATC was notably represented by downregulation of genes encoding critical thyroid transcription factors and proteins important for thyroid hormones metabolism. Furthermore, deregulated gene sets were related to different cell junctions, to cell-cell adhesion and to actin cytoskeleton, reflecting the loss of the epithelial morphology and transition to a mesenchymal state. Loss of epithelial phenotype is a key process in activation of epithelial-to-mesenchymal transition (EMT), whereby epithelial cells lose contact, undergo cytoskeleton remodeling and manifest a higher migratory phenotype (25) . In our gene expression analysis, ATC presented defining features of EMT, such as the downregulation of CDH1 gene (E-cadherin) (8, 22, 26) and gain of mesenchymal markers, like fibronectin (22, 27) and WNT5A. Moreover, as described before (8, 22) , we detected overexpression of TGF-␤ signaling components (TGFBI, TGFB1, LTBP1, TGFBR1), which suggests an autocrine pathway, potentially relevant due to its role in the promotion of EMT (25) . A recent report described the activation of EMT program in mammary cells (28) , by combined autocrine loops of TGF-␤ signaling and WNT signaling (through WNT5A). Most interesting, induction of EMT had to be accompanied by reduced levels of inhibitors of these pathways, such as BMP, which we also found to be downregulated in ATC. In PTC samples, increased TGF-␤1 staining was present at the invasive fronts (29) , where an EMT-like expression profile was found (30) . Interestingly, despite the low detection of BRAF mutations (2 in 26), and presenting mostly underexpressed genes (similarly to PDTC and FTC), ATC shared more common differentially expressed genes (relatively to normal thyroid) with cPTC. This observation is in agreement with recent work (22) , reporting that 43% of the genes deregulated in PTC were similarly regulated in 11 ATC (2 with mutated BRAF) and suggests that ATC could derive from PTC through a progressive transition to an undifferentiated and more mesenchymal state. For PDTC, similarity with cPTC was not evident and genes related to EMT were not found (10), probably because our series did not include PDTC with associated classical papillary components. Nevertheless, analysis of paired PDTC-PTC foci from BRAF mutant mice, did reveal a characteristically EMT gene profile in PDTC, which was driven by concomitant MAPK and TGF-␤ signaling (31) . So, upon MAPK constitutive activation, TGF-␤ may be the key promoter of invasion and metastasis in ATC and papillary-associated PDTC. In our search for ATC therapeutic targets, we observed the specifically overexpression of SNAI2 gene in our ATC series (2.24-fold relatively to normal), which in combination with activation of the epithelial-to-mesenchymal transition and TGF-␤ signaling, prompted us to validate this gene by quantitative RT-PCR. The SNAI2 gene encodes a zinc-finger transcription factor that represses the expression of the epithelial marker, E-cadherin, as well as other epithelial components like occludin, claudins, and cytokeratins (32) . In addition, SNAI2 is one effector of the epithelial-to-mesenchymal transition, which is induced in response to TGF-␤ (32) . Several data indicate that SNAI2 has a crucial role, by integrating proliferation, apoptosis and differentiation signals (32, 33) , and by participating in tumorigenesis induced by RAS (34) and TP53 mutants (35) . Accordingly, among the subgroup of 8 ATC, that clearly expressed higher SNAI2 levels (representing 42% of the ATC tumors), 3 had RAS mutations, 3 had TP53 mutations and one was mutated for both genes. However, we were unable to identify other clinical or histological parameters that correlated with the SNAI2 overexpression in the subgroup of 8 ATC.
Another pathway contributing to EMT (25) , and shown to be involved in thyroid cancer, is WNT/␤-catenin signaling. Prior results showed that decreased ␤-catenin expression (26) or aberrant nuclear expression (42%-48%) and CTNNB1 exon 3 mutations (61%-65%) were involved in ATC development (5, 36) . However, Kurihara and collaborators found CTNNB1 mutations only in 4.5% and APC mutations in 9% of ATC, pointing out AXIN1 gene (mutated in 82%) as the main altered component of WNT pathway (11). Hébrant et al also found no CTNNB1 mutations in 11 ATC (22) . In PDTC, ␤-catenin mutations and nuclear expression were present in 25% and 21% of cases, respectively (5), whereas in other 17 cases, no alterations were found (37) . Unexpectedly, our mutational analysis only revealed three different germ-line AXIN1 variants (two predicted in silico to be pathogenic and one to be benign), and a single CTNNB1 mutation in a PDTC that also harbored mutations in other genes, undermining a major role for this pathway. More mutational analyses are required to elucidate the observed discrepancies and to clarify the importance of this pathway in thyroid progression.
The present study showed ATC gene expression was deregulated for gene sets related to cell cycle regulation and checkpoints, chromosome segregation and spindle structure. Thus, similarly to PDTC (10), ATC have upregulation of genes related to proliferation, cell cycle (22) and chromosomal instability (7) . Progression through the cell cycle may be controlled by the interaction of cyclindependent kinases (CDK) and cyclins complexes, with CDKI. Based on sequence homology and CDK specificity, CDKI are divided into two distinct families, INK4 members (p16   INK4A   , p15   INK4B   , p18 INK4C and p19
INK4D
) and CIP/KIP members (p21 CIP1 , p27 KIP1 and p57 KIP2 ). In addition, all CIP/KIP may be involved in actin dynamics and cell migration. Upon cytoplasmic mislocalization, CIP/ KIP proteins regulate, at distinct levels, the Rho pathway, promoting cell motility and invasion (38) . This suggests that rather than being inactivated, CIP/KIP members are subverted for increased tumorigenesis, justifying the lower frequency of CDKN1A (p21 (39) found CDKN2B mRNA expression to be normal in 5 ATC, and except for the role of the p18 INK4C in medullary thyroid carcinoma, CDKN2C (or p18 INK4C protein) has never been studied in thyroid tumors. CDKN2A decreased expression and/or hypermethylation have been frequently reported in ATC and PDTC (40, 41) but, in agreement with our results, mutations were uncommon in ATC (39, 42) . To our knowledge, we demonstrated for the first time that mutations in CDKI family might be involved in up to 20% of PDTC and in up to 14% of ATC.
Interestingly, the most overexpressed gene found in ATC (CDKN3) is also a CDKI. This gene encodes a dualspecificity phosphatase that blocks G1/S phase progression through CDK2 kinase dephosphorylation. However, CDKN3 was found to be overexpressed, and to increase neoplastic transformation, in breast and prostate cancer (43) . These contradictory observations were clarified upon the findings in glioblastoma, in which upregulation was associated with increased aberrant splicing and loss of full-length protein (44) . Upon the finding that CDKN3 was the most overexpressed gene in ATC, we investigated the presence of aberrant splicing, similarly to that described for glioblastoma. We showed that CDKN3 is aberrantly spliced, specifically in ATC, but did not observe the spliced form described for glioblastoma, in which exon 3 is lost. The splice variants found lacked exon 2, which is predicted to originate a truncated protein of only 23 amino acids. It remains to clarify if these variant could inhibit the full-length CDKN3 transcription or if an abnormal peptide may be translated and affect the CDKN3 functions.
We found that PIK3CA mutations were more prevalent in PDTC (3/22) than in ATC (1/26), and coexisted with other alterations. Indeed, prior studies in ATC, found PIK3CA mutations/copy number gains to be overlapped with BRAF, RAS mutations or p53 increased expression (3, 6, 45) , suggesting that PIK3CA alterations often cooperate with other oncogenic events in these type of tumors. Unexpectedly, the frequency of PIK3CA mutations in our ATC samples (4%) is lower than the reported in the literature (12%-23%). Phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway can also be aberrantly activated through inactivation of PTEN, a negative regulator of the pathway. Previous studies have not found PTEN mutations in ATC (46, 47) or alterations were present in only 6%-16% of the samples (3, 45) . In our analysis, PTEN alterations were identified in 2 ATC (10%) and were also detected in 3 PDTC (20%).
Our results corroborated p53 inactivation, rather than CTNNB1 and PIK3CA mutations, as the main event in ATC and PDTC progression. Prior results (20) have shown that PDTC and ATC patients presenting TP53 mutation had decreased survival, stressing its major influence in tumorigenesis. In our study, RAS was the second most mutated gene, whereas BRAF mutations were present in only 3 samples, as expected for a series with no histological evidence of PTC derivation (48, 49) . Our detection of mutated RAS is in agreement with other PDTC (50) and ATC (2, 51) studies. From progression point of view (Supplemental Figure 6 ), it may be suggested that these dedifferentiated tumors derive from RAS-mutated WDTC, that is, FTC and/or fvPTC. In our previous work (10) , based on the similarity of gene expression profile, we suggested fvPTC as plausible precursors of RAS-mutated PDTC. In contrast, our and others (22) expression analysis suggested that ATC were molecularly more similar to cPTC.
Rather than a common origin, this may suggest a molecular mechanism affecting both cPTC and ATC (for example TGF-␤ activation). In either case, our work suggests that RAS and TP53 mutations are alternative events, rather than progressively accumulated events, during PDTC and ATC progression (2) .
Overall, 9 PDTC (41%) and 6 ATC (23%) harbored no mutations in the 14 genes profiled. Other mechanisms may be driving progression in these tumors, and further molecular characterization is required, especially for PDTC. The application of next-generation sequencing, which has a lower limit of detection when compared with the Sanger sequencing, could reveal new ATC and PDTC driver mutations occurring in samples with a low percentage of tumor cells, as well as, the evaluation of the intratumor genetic heterogeneity. For Sanger sequencing, the limit of detection by visual inspection of the electropherogram has been described to be around 15%-20% of mutant alleles (52) (53) (54) , which corresponds to about 30%-40% of mutant cells (for a heterozygous alteration). This may represent a drawback in the technique since PDTC and ATC have been found to be densely infiltrated with tumor-associated macrophages (55) , representing 50 to 60% of the nucleated cells in ATC (56) . Nevertheless, it is interesting to note that in our work, we have actually detected more mutated ATC samples (77%) than PDTC mutated samples (59%), despite the fact that macrophage infiltration occurs more frequently in ATC.
For the mutated cases found, different therapeutic approaches are available depending on the alteration uncovered. The present work, points out additional targets that may be used, alone or in combination. The detection of TP53 mutations in 27% PDTC and 42% ATC allows the use of molecules for reactivation of the p53 functions (57) . The deregulated profile related to proliferation, CDKI mutations (in 20% PDTC and 14% ATC) and CDKN3 abnormal splicing in ATC, suggest that inhibitors of CDK, for example roscovitine and flavopiridol, may be efficient in such cases (58) . SNAI2 overexpression in 42% of cases and the likely influence of TGF-␤ signaling in ATC, suggest that TGF-␤ inhibitors, which some are already in clinical trials (59) , represent also a reasonable therapeutic option. This work was funded by Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), and received the award "Prémio Nacional de Endocrinologia -SPEDM/Novartis Oncology 2012".
